REGENERON PHARMACEUTICALS (1REGN.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1REGN - US75886F1075 - Common Stock
603.8 EUR
+105.6 (+21.2%)
Overall 1REGN gets a fundamental rating of 7 out of 10. We evaluated 1REGN against 78 industry peers in the Biotechnology industry. 1REGN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. 1REGN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year 1REGN was profitable.
1REGN had a positive operating cash flow in the past year.
In the past 5 years 1REGN has always been profitable.
In the past 5 years 1REGN always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 11.40%, 1REGN belongs to the best of the industry, outperforming 87.18% of the companies in the same industry.
1REGN's Return On Equity of 14.79% is amongst the best of the industry. 1REGN outperforms 87.18% of its industry peers.
Looking at the Return On Invested Capital, with a value of 8.25%, 1REGN belongs to the top of the industry, outperforming 85.90% of the companies in the same industry.
1REGN had an Average Return On Invested Capital over the past 3 years of 11.81%. This is in line with the industry average of 12.34%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 8.25% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)11.81%
ROIC(5y)17.22%
1.3 Margins
The Profit Margin of 1REGN (32.13%) is better than 91.03% of its industry peers.
1REGN's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 27.61%, 1REGN belongs to the best of the industry, outperforming 85.90% of the companies in the same industry.
In the last couple of years the Operating Margin of 1REGN has declined.
Looking at the Gross Margin, with a value of 86.28%, 1REGN is in the better half of the industry, outperforming 76.92% of the companies in the same industry.
In the last couple of years the Gross Margin of 1REGN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
1REGN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, 1REGN has about the same amount of shares outstanding.
The number of shares outstanding for 1REGN has been reduced compared to 5 years ago.
Compared to 1 year ago, 1REGN has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 7.07 indicates that 1REGN is not in any danger for bankruptcy at the moment.
1REGN has a Altman-Z score of 7.07. This is amongst the best in the industry. 1REGN outperforms 84.62% of its industry peers.
1REGN has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
The Debt to FCF ratio of 1REGN (0.70) is better than 91.03% of its industry peers.
1REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.09, 1REGN is doing good in the industry, outperforming 62.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 7.07 |
ROIC/WACC0.98
WACC8.41%
2.3 Liquidity
A Current Ratio of 4.06 indicates that 1REGN has no problem at all paying its short term obligations.
1REGN has a Current ratio of 4.06. This is in the better half of the industry: 1REGN outperforms 76.92% of its industry peers.
1REGN has a Quick Ratio of 3.51. This indicates that 1REGN is financially healthy and has no problem in meeting its short term obligations.
1REGN has a Quick ratio of 3.51. This is in the better half of the industry: 1REGN outperforms 69.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
1REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.92%.
1REGN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.12% yearly.
Looking at the last year, 1REGN shows a small growth in Revenue. The Revenue has grown by 2.89% in the last year.
Measured over the past years, 1REGN shows a quite strong growth in Revenue. The Revenue has been growing by 12.55% on average per year.
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
3.2 Future
Based on estimates for the next years, 1REGN will show a small growth in Earnings Per Share. The EPS will grow by 6.38% on average per year.
Based on estimates for the next years, 1REGN will show a small growth in Revenue. The Revenue will grow by 5.63% on average per year.
EPS Next Y-6.32%
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
EPS Next 5Y6.38%
Revenue Next Year-0.32%
Revenue Next 2Y2.42%
Revenue Next 3Y4.76%
Revenue Next 5Y5.63%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 15.45, the valuation of 1REGN can be described as correct.
Based on the Price/Earnings ratio, 1REGN is valued cheaply inside the industry as 87.18% of the companies are valued more expensively.
1REGN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.31.
Based on the Price/Forward Earnings ratio of 15.66, the valuation of 1REGN can be described as correct.
Based on the Price/Forward Earnings ratio, 1REGN is valued cheaply inside the industry as 91.03% of the companies are valued more expensively.
1REGN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.45 | ||
| Fwd PE | 15.66 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1REGN indicates a somewhat cheap valuation: 1REGN is cheaper than 79.49% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, 1REGN is valued cheaply inside the industry as 84.62% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.84 | ||
| EV/EBITDA | 13.78 |
4.3 Compensation for Growth
The excellent profitability rating of 1REGN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.18
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
5. Dividend
5.1 Amount
1REGN has a yearly dividend return of 0.48%, which is pretty low.
Compared to an average industry Dividend Yield of 12.49, 1REGN pays a better dividend. On top of this 1REGN pays more dividend than 92.31% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, 1REGN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.48% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
BIT:1REGN (11/13/2025, 7:00:00 PM)
603.8
+105.6 (+21.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners90.24%
Inst Owner ChangeN/A
Ins Owners1.89%
Ins Owner ChangeN/A
Market Cap63.46B
Revenue(TTM)14.25B
Net Income(TTM)4.58B
Analysts80.59
Price Target657.38 (8.87%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.48% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)3.82%
PT rev (3m)2.98%
EPS NQ rev (1m)12.95%
EPS NQ rev (3m)14.51%
EPS NY rev (1m)6.84%
EPS NY rev (3m)18.44%
Revenue NQ rev (1m)3.42%
Revenue NQ rev (3m)4.21%
Revenue NY rev (1m)1.81%
Revenue NY rev (3m)5.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.45 | ||
| Fwd PE | 15.66 | ||
| P/S | 5.13 | ||
| P/FCF | 18.84 | ||
| P/OCF | 14.42 | ||
| P/B | 2.36 | ||
| P/tB | 2.47 | ||
| EV/EBITDA | 13.78 |
EPS(TTM)39.07
EY6.47%
EPS(NY)38.56
Fwd EY6.39%
FCF(TTM)32.05
FCFY5.31%
OCF(TTM)41.88
OCFY6.94%
SpS117.68
BVpS255.69
TBVpS244.29
PEG (NY)N/A
PEG (5Y)1.18
Graham Number474.1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROCE | 11.01% | ||
| ROIC | 8.25% | ||
| ROICexc | 10.81% | ||
| ROICexgc | 11.38% | ||
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% | ||
| FCFM | 27.24% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)11.81%
ROIC(5y)17.22%
ROICexc(3y)17.18%
ROICexc(5y)23.98%
ROICexgc(3y)18.1%
ROICexgc(5y)24.53%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.61 | ||
| Cap/Depr | 226.62% | ||
| Cap/Sales | 8.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.73% | ||
| Profit Quality | 84.78% | ||
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 7.07 |
F-Score5
WACC8.41%
ROIC/WACC0.98
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
EPS Next Y-6.32%
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
EPS Next 5Y6.38%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
Revenue Next Year-0.32%
Revenue Next 2Y2.42%
Revenue Next 3Y4.76%
Revenue Next 5Y5.63%
EBIT growth 1Y-6.18%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-14.02%
EBIT Next 3Y4.25%
EBIT Next 5Y10.18%
FCF growth 1Y-10.97%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-2.93%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%
REGENERON PHARMACEUTICALS / 1REGN.MI FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 7 / 10 to 1REGN.MI.
What is the valuation status for 1REGN stock?
ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (1REGN.MI). This can be considered as Fairly Valued.
What is the profitability of 1REGN stock?
REGENERON PHARMACEUTICALS (1REGN.MI) has a profitability rating of 8 / 10.
What is the earnings growth outlook for REGENERON PHARMACEUTICALS?
The Earnings per Share (EPS) of REGENERON PHARMACEUTICALS (1REGN.MI) is expected to decline by -6.32% in the next year.